Practice and management of residual breast cancer burden after neoadjuvant therapy / 中华内分泌外科杂志

ABSTRACT

The application of neoadjuvant therapy in treatment of breast cancer is increasing. Residual cancer burden (RCB) provides valuable prognosis information for patients, which can be used as the main end point of clinical trials. This review summarizes the difficulties and key points in the RCB evaluation, including the experience of tumor bed locating and sampling, and microscopic evaluation of the elements specific to RCB and the application of multidisciplinary cooperation in the whole process, and put forward some management methods to address these challenges, making it possible to standardize RCB evaluation and ordered quality control management.